Drug
OF Kx2 391 1
OF Kx2 391 1: highest development phase Phase 2, developed by Almirall. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| 50 mg of KX2-391 Ointment 1% NCT02838628 | Phase 2 | Actinic Keratosis |
Latest
No recent events.
Follow OF Kx2 391 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.